# Meta-Reflection

## Executive Summary
- **Post ID**: Zepbound Q4 2025 Revenue question
- **Final forecast**: Central estimate ~$4,400M with wide distribution ($3,600M-$5,400M at 80% CI)
- **Confidence level**: Moderate - good historical data but unable to find actual Q4 2025 results

## Research Audit

### Searches Performed
1. Metaculus question details (returned wrong question ID)
2. Exa search for Eli Lilly Q4 2025 earnings - found Q4 2024 and Q3 2025 data
3. Statista historical revenue data - excellent source for Q1 2024 through Q3 2025
4. Analyst estimates from early 2025 - useful for context but outdated
5. Stock price check - LLY trading at ~$1,064
6. Multiple searches for Q4 2025 actual results - unsuccessful

### Most Informative Sources
- Statista: Complete quarterly revenue history Q1 2024 - Q3 2025
- Q3 2025 earnings release: Eli Lilly raised 2025 guidance to $63-63.5B
- CNBC Feb 2025 article: Analyst expectations context

### Tool Effectiveness
- **search_exa**: Good for historical data, struggled to find Feb 2026 news (may not be indexed yet)
- **web_search**: Similar limitations
- **stock_price**: Worked correctly
- **execute_code**: Excellent for Monte Carlo simulation
- **WebFetch on investor.lilly.com**: Failed with archive.org error

## Reasoning Quality Check

**Strongest evidence FOR my forecast (~$4,300-4,500M central):**
1. Historical seasonality: Q4 2024 was 52% higher than Q3 2024
2. YoY growth has been ~185%, suggesting Q4 2025 should significantly exceed Q4 2024 ($1,907M)
3. Eli Lilly raised guidance in Q3, suggesting confidence in Q4

**Strongest argument AGAINST my forecast:**
- Recent QoQ growth slowed dramatically (only 6% Q2→Q3 2025)
- Could indicate product maturation or supply constraints
- Competition from Wegovy and compounding pharmacies may intensify

**Calibration check:**
- Question type: Measurement (numeric, what will value be?)
- Applied appropriate uncertainty given inability to find actual results
- Wide 80% CI accounts for seasonal and competitive uncertainty

## Subagent Decision
Did not use subagents - this was a straightforward data lookup question where:
1. Historical data was readily available
2. The main challenge was finding actual Q4 2025 results (subagents wouldn't help)
3. Monte Carlo simulation was sufficient for uncertainty quantification

## Process Feedback
- Prompt guidance on checking resolution source was useful
- Would have benefited from a more reliable financial data tool for recent earnings
- The question may have already resolved given the date

## Calibration Tracking
- **80% CI**: $3,600M - $5,400M
- **Comparable questions**: Pharmaceutical product revenue forecasts
- **Update triggers**: If actual results released, would immediately anchor on reported figure
---

## Programmatic Metrics

*Auto-generated - do not edit manually*

- **Post ID**: 41747
- **Question ID**: 41487
- **Session Duration**: 335.2s (5.6 min)
- **Cost**: $1.0819
- **Tokens**: 14,148 total (104 in, 14,044 out)
  - Cache: 637,153 read, 65,870 created
- **Log File**: `logs/41747_20260207_042700/20260207_042701.log`

### Tool Calls

- **Total**: 24 calls
- **Errors**: 0 (0.0%)

| Tool | Calls | Errors | Avg Time |
|------|-------|--------|----------|
| execute_code | 3 | 0 | 305ms |
| get_metaculus_questions | 1 | 0 | 744ms |
| get_prediction_history | 1 | 0 | 0ms |
| notes | 3 | 0 | 2ms |
| search_exa | 13 | 0 | 6425ms |
| stock_price | 1 | 0 | 790ms |
| web_search | 2 | 0 | 4637ms |

### Sources Consulted

- Eli Lilly Q4 2025 earnings Zepbound revenue results
- Eli Lilly Q4 2025 earnings Zepbound revenue January February 2026
- "Zepbound" "Q4 2025" OR "fourth quarter 2025" revenue sales billion
- Eli Lilly investor relations quarterly results 2025 annual report
- Eli Lilly earnings report February 2026 fourth quarter results
- https://investor.lilly.com/financial-information/quarterly-results
- LLY Eli Lilly stock earnings Q4 results announcement date January 2026
- Zepbound Q4 2025 analyst estimate forecast revenue projection
- Eli Lilly 2025 guidance Zepbound full year revenue annual forecast Wall Street
- "Zepbound" 2025 "full year" OR "annual" revenue sales billion forecast estimate
- Eli Lilly earnings call transcript Q4 2025 Zepbound fourth quarter billion
- LLY Eli Lilly stock earnings report 2026 February quarterly results revenue
- Zepbound 2025 full year revenue estimate analyst expectations Wall Street for...
- Eli Lilly Q4 2025 earnings date announcement when February